Abstract
AURKA promoted UM progression by driving angiogenesis through the JAK2/STAT3/VEGFA signaling pathway. ART effectively inhibited the function of AURKA, offering a promising therapeutic strategy for UM. The synergistic effects of ART and knocking down AURKA further highlighted its potential as a novel anti-angiogenic therapy for UM.
Introduction
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Despite successful local treatment of the primary tumor, nearly half of patients develop metastatic disease, primarily in the liver, where the prognosis is dismal with a median survival of approximately six months. A critical driver of UM progression is angiogenesis—the formation of new blood vessels that supply the tumor with essential nutrients and oxygen.
Recent research has identified Aurora kinase A (AURKA), a protein traditionally associated with mitosis, as a key regulator of this angiogenic process. This study explores the mechanism by which AURKA drives angiogenesis via the JAK2/STAT3/VEGFA signaling axis and evaluates the therapeutic potential of Artesunate (ART), a derivative of Artemisia annua, in inhibiting this pathway.
Methods
The study utilized a comprehensive experimental framework:
- Bioinformatics Analysis: Data from The Cancer Genome Atlas (TCGA-UVM) was analyzed to determine the prognostic significance of AURKA expression using Kaplan–Meier survival curves and Cox regression models.
- In Vitro Angiogenesis Assays: Human umbilical vein endothelial cells (HUVECs) were used in tube formation and migration assays to assess the pro-angiogenic effects of UM cell-conditioned media.
- Chicken Chorioallantoic Membrane (CAM) Assay: An ex vivo model was employed to observe real-time vascular development in response to tumor signaling.
- Molecular Modeling: Computational docking (AutoDock Vina) and molecular dynamics (MD) simulations (GROMACS) were performed to characterize the binding affinity and stability of the ART-AURKA complex.
- In Vivo Xenograft Model: Nude mice were used to evaluate the anti-tumor and anti-angiogenic efficacy of ART and AURKA knockdown in a subcutaneous tumor model.
Results
Prognostic Impact of AURKA
Analysis of clinical datasets revealed that high AURKA expression is a strong independent predictor of poor survival in UM patients. Time-dependent ROC analysis yielded an Area Under the Curve (AUC) of 0.818 for 5-year overall survival, confirming its potential as a reliable biomarker.
Mechanism of Angiogenesis
AURKA was found to activate the JAK2/STAT3/VEGFA signaling pathway. Knockdown of AURKA significantly reduced the expression of VEGFA and inhibited the ability of UM cells to induce endothelial cell migration and tube formation.
Therapeutic Efficacy of Artesunate
Computational simulations demonstrated that ART binds stably to AURKA at residues ASP-274, THR-217, and LEU-139, with a binding free energy of -31.04 kcal/mol. In animal models, treatment with ART (75 mg/kg) significantly suppressed tumor growth. The most profound effects were observed when ART was combined with AURKA knockdown, leading to a marked reduction in the expression of the angiogenic marker CD31 and the proliferation marker Ki67.
Discussion
This study elucidates a novel role for AURKA in UM, extending its function beyond cell cycle regulation to the promotion of angiogenesis. By activating the JAK2/STAT3/VEGFA axis, AURKA facilitates the vascularization necessary for tumor growth and metastasis.
Artesunate emerges as a potent pharmacological inhibitor of this process. Its ability to stabilize AURKA and disrupt downstream signaling suggests it could be repurposed as a targeted therapy for UM. However, certain limitations remain. The use of a subcutaneous rather than an orthotopic (intraocular) mouse model may not fully capture the unique ocular microenvironment. Additionally, while computational data is compelling, physical validation of the direct ART-AURKA interaction through biochemical assays is a necessary next step.
Conclusion
AURKA is a pivotal driver of angiogenesis in uveal melanoma. Targeting the AURKA/JAK2/STAT3/VEGFA pathway with Artesunate represents a promising therapeutic strategy to combat tumor progression and improve outcomes for patients with this aggressive malignancy.
Summary updated